ASCO 2015 Highlights


Learn about how clinical research trials are revolutionizing radiotherapy, leading to advancements reshaping cancer care for better patient outcomes and experiences.
Read Article

A coalition of more than 40 health insurers recently announced plans for prior authorization reform.
Read Article

In a roundtable discussion hosted by HHS, health insurers pledged 6 key reforms they say are designed to cut red tape, accelerate care decisions, and enhance
Read Article

The phase 3 S2302 Pragmatica-Lung study offers a new blueprint for cancer clinical trials, one that emphasizes simplification, inclusivity, and real-world applicability, according to Konstantin Dragnev, MD, of Dartmouth Cancer Center.
Read Article

AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer
We are delighted to announce the release of our next issue of Clinical Trials to Clinical Practice. This piece provides expert insights from Vamsi Velcheti, MD, MBA, FASCO, FACP, FCCP, regarding the outcomes of patients with ROS1-positive non–small cell lung cancer treated with AUGTYRO in the phase 1-2 TRIDENT-1 study.
Read Article

Paula Aristizabal, MD, MAS, a pediatric hematologist/oncologist at Rady Children’s Hospital-San Diego/associate professor at the University of California San Diego, and her research team developed a peer navigation intervention known as the Childhood Malignancy Peer Research Navigation (Comprendo) program. This program pairs trained parent navigators—individuals who have experienced similar challenges with their own children’s cancer care—with parents who are newer to the experience, with the intention to guide these families through the informed consent process for childhood cancer clinical trials.
Read Article

Value-Based Cancer Care is pleased to share with you that we are on site at the 21st Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, April 9-12, 2025, in Portland, OR and together with our sister publication, the Journal of Hematology Oncology Pharmacy,we are bringing you live coverage and abstracts from the meeting.
Read Article

n the US cohort, Black patients with HR-positive/HER2-negative mBC who underwent NGS testing were more likely to receive first-line chemotherapy, less likely to have PIK3CA mutations, and less likely to receive first-line CDK4/6 inhibitors compared with White patients.
Read Article

round Zero were 3 times more likely to have genetic changes associated with an increased risk of blood cancer compared with other first responders.
Read Article

Page 2 of 329